Graphite Bio Inc
NASDAQ:LENZ

Watchlist Manager
Graphite Bio Inc Logo
Graphite Bio Inc
NASDAQ:LENZ
Watchlist
Price: 16.48 USD 3%
Market Cap: 515.7m USD

Graphite Bio Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Graphite Bio Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Graphite Bio Inc
NASDAQ:LENZ
Cash from Operating Activities
-$59.4m
CAGR 3-Years
-4%
CAGR 5-Years
-395%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

Graphite Bio Inc
Glance View

Market Cap
469.7m USD
Industry
Biotechnology

Graphite Bio, Inc. operates as a clinical-stage gene editing company. The company is headquartered in South San Francisco, California and currently employs 120 full-time employees. The company went IPO on 2021-06-25. The firm has a gene editing platform that is designed to correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its research program, GPH102 for the treatment of beta-thalassemia, leverages its gene replacement platform technology by replacing one or both copies of the mutated beta-globin (HBB) gene through HDR to restore HgbA expression to levels. GPH201 is an investigational treatment for X-linked severe combined immunodeficiency syndrome (XSCID), a rare, life-threatening disease where multiple mutations in a single gene (IL2RG) prevent normal immune system function. GPH301 is for the treatment of Gaucher disease. Its pipeline program also includes therapeutic protein production and non-genotoxic conditioning (NGTC).

LENZ Intrinsic Value
33.19 USD
Undervaluation 50%
Intrinsic Value
Price

See Also

What is Graphite Bio Inc's Cash from Operating Activities?
Cash from Operating Activities
-59.4m USD

Based on the financial report for Dec 31, 2024, Graphite Bio Inc's Cash from Operating Activities amounts to -59.4m USD.

What is Graphite Bio Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-395%

Over the last year, the Cash from Operating Activities growth was 34%. The average annual Cash from Operating Activities growth rates for Graphite Bio Inc have been -4% over the past three years , -395% over the past five years .

Back to Top